CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $850,400 | +4713.8% | 47,192 | +4190.2% | 0.01% | – |
| Q1 2023 | $17,666 | -53.5% | 1,100 | -42.9% | 0.00% | – |
| Q3 2022 | $38,000 | -75.9% | 1,925 | -77.3% | 0.00% | -100.0% |
| Q2 2022 | $158,000 | +45.0% | 8,478 | +70.4% | 0.00% | 0.0% |
| Q1 2022 | $109,000 | +137.0% | 4,975 | +205.8% | 0.00% | – |
| Q4 2021 | $46,000 | -89.6% | 1,627 | -92.2% | 0.00% | -100.0% |
| Q3 2021 | $441,000 | +90.9% | 20,938 | +70.5% | 0.01% | +100.0% |
| Q2 2021 | $231,000 | – | 12,281 | +72141.2% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 17 | -98.5% | 0.00% | – |
| Q4 2020 | $16,000 | -38.5% | 1,168 | -21.2% | 0.00% | – |
| Q2 2020 | $26,000 | -78.0% | 1,483 | -68.4% | 0.00% | -100.0% |
| Q4 2019 | $118,000 | +337.0% | 4,700 | +164.3% | 0.00% | +100.0% |
| Q3 2019 | $27,000 | – | 1,778 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |